Article Text

Download PDFPDF
Cochrane corner: PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease

Statistics from


  • Contributors J-PC drafted the manuscript, all coauthors provided critical input.

  • Funding AFS is supported by BHF grant PG/18/5033837. ADH is an NIHR Senior Investigator. Both AFS and ADH acknowledge support by the UCL BHF Research Accelerator AA/18/6/34223 award. JW reports receiving grants from the NHLBI.

  • Disclaimer This review is an abridged version of a Cochrane Review previously published in the Cochrane Database of Systematic Reviews 2020, Issue 10, DOI: /10.1002/14651858.CD011748.pub3 (see for information). Cochrane Reviews are regularly updated as new evidence emerges and in response to feedback, and Cochrane Database of Systematic Reviews should be consulted for the most recent version of the review.

  • Competing interests AFS has received Servier funding for unrelated work.

  • Patient and public involvement Patients and/or the public were involved in the design, or conduct, or reporting, or dissemination plans of this research. Refer to the Methods section for further details.

  • Provenance and peer review Commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.